Skip to content

ADMA Biologics ADMA Plasma Collection Centers — General And Administrative Expense

Other segment segments

ADMA Bio Manufacturing
$8.46M-0.4%

Similar metrics at other companies

Haemonetics logo
HAEPlasma — SG&A
$27.27M+11.3%
Haemonetics logo
HAEBlood Center — SG&A
$13.48M-9.6%
AnaptysBio, Inc. logo
ANABBiopharma Company — General And Administrative Expense
$18.86M+92.1%
Starwood Property Trust logo
STWDProperty Segment — G&A
$8.87M+527%
Haemonetics logo
HAEPlasma — Cost of goods sold
$54.39M+14.9%
The Carlyle Group logo
CGGlobal Private Equity — General, administrative and other expenses
$53.9M+10.7%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.02B-54.5%

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's plasma collection centers — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's plasma collection centers — general and administrative expense?
ADMA Biologics (ADMA) reported plasma collection centers — general and administrative expense of $0 in Q1 2026.
What does plasma collection centers — general and administrative expense mean?
Covers the overhead costs associated with managing the plasma collection segment, including administrative staff, facility management, and compliance oversight. This metric helps evaluate the scalability of the segment's management structure. Lower G&A as a percentage of revenue indicates improved operational leverage.